BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out ...

BioNTech is losing its chief strategy officer, with Ryan Richardson set to leave the company at the end of September to ...

On June 12, 2025, BioNTech SE (“BioNTech”) announced its entry into a definitive purchase agreement to acquire all shares of CureVac N.V. (“CureVac”), with an implied aggregate equity ...

CureVac N.V. (NASDAQ:CVAC) is among the 13 Best German Stocks to Invest in Now. The stock has gained by over 16% in the past month, with a major surge following the June 12 announcement that the ...

CureVac N.V. (NASDAQ: CVAC) is among the 13 Best German Stocks to Invest in Now. The stock has gained by over 16% in the past month, with a major surge following the June 12 announcement that the ...

Later in the month, on June 12, BioNTech SE (NASDAQ:BNTX) announced that it would acquire CureVac for approximately $1.25 billion in shares, which is expected to further strengthen the company’s ...

Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma ...

Review the current CureVac NV Ordinary Shares (CVAC:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if CVAC is the best investment for you.

The Food and Drug Administration (FDA) has expanded its warnings on Pfizer and Moderna COVID-19 vaccines about the risks of two heart conditions. These manufacturers, the two main COVID-19 vaccine ...